Sanja Selak, PhD
Chief Executive and Scientific Officer (CEO/CSO)
Sanja is Origimm’s founder and inventor with more than 25 years of experience in immunology, serology, microbiology and antigen discovery.
Besides managing and leading business and scientific strategy, she also dedicates significant attention to innovation and team development.
Sanja had studied and worked at world renowned academic institutes around the globe including the Faculty of Medicine, University of Calgary, Canada; Marine Biological Laboratory (MBL), Woods Hole, MA, USA; and the Neurobiology Institute Ramon y Cajal in Madrid.
Sanja was previously Head of Department of Serology and Immune Assays at Intercell AG (Valneva), where she managed various collaborative projects and evaluated the efficacy of product candidates from the early discovery to phase II clinical trials. She distinguished herself for accurately predicting the success of various vaccine candidates in clinical trials based on sophisticated methods for antigen validation that she designed and developed.
For Sanja, science is the highest form of art accomplished by creative imagination. This approach stems from her music background: Sanja is also an accomplished pianist and musician.
More about Sanja at: https://at.linkedin.com/in/sselak
Manfred Schuster, PhD
Chief Development Officer (CDO)
Manfred has more than twenty years of experience in pharmaceutical and biotech industry. As CEO, COO or program manager, he co-founded or developed the biotech companies Igeneon AG, Apeiron Biologics AG, RMB Research and RemuteBio.
At Origimm, Manfred is responsible for the non-clinical and pre-clinical activities required for the product characterization, development and clinical trial approval. He is also managing various external collaborations, internal infrastructure and regulatory operations.
Manfred is certified as Qualified Person, holds a PhD degree from the University of Natural Resources of Vienna, a Master of Science Engineer degree in technical chemistry, biochemistry and biotechnology from the Technical University of Vienna and a Master of Science degree in pharmaceutical quality management from the University of Vienna.
Manfred worked many years as the executive board member and program manager for early and late stage clinical development programs against cancer, including vaccines and antibody therapeutics. He developed an orphan antibody-based immuno-therapy against neuroblastoma until submission for market approval in Europe, and enzyme substitution therapy from the idea until an exclusive license deal of € 250 M with Glaxo-SmithKline in Phase II.
Besides working hard on improving the lives of patients, Manfred is also contributing to societal values as a qualified fire safety engineer and lifeguard trainer.
Thomas Fischer, MBA
Chief Financial Officer (CFO)
Thomas has a long track record working in the life science industry. He held CEO and CFO positions in EUCODIS Bioscience, an industrial enzyme-developing company, he also co-founded AUSTRIANOVA, a clinical stage biopharmaceutical company, where he held the position of CFO. Thomas also held executive and supervisory positions at AVENTIS CropScience and NYCOMED Pharma Group.
Thomas started his entrepreneurial career in 1986, in parallel to studying for his MBA at the Vienna University of Economics and Business. He founded his first start-up in Slovakia, followed by co-founding a company group specialized in fast moving consumer goods distribution in central Europe and Russia.
Besides building companies, Thomas also enjoys learning about quantum physics, hiking and playing tennis.
Martin Steiner, PhD, MBA
Head of Business Development
Martin has more than 20 years experience in the pharma and biotechnology industry with particular focus on general management and funding of start-up companies as well as business development and corporate strategy.
Martin obtained a PhD in Microbiology and Genetics from the University of Vienna and an MBA from the University of Michigan.
He started his professional career as Manager Business Development at SmithKline Beecham Biologicals. He then founded and led two biotechnology companies as CEO, Apovia AG a vaccine development company and ImVisioN Therapeutics an allergy immunotherapy company, which developed products from bench to clinical proof-of-concept. For these companies he raised more than € 35 million form private and institutional investors in several financing rounds. Over the last eight years, Martin has been an independent consultant to several biotechnology and MedTech companies advising in the fields of business and strategy development as well as fund raising.